10x Genomics's (NASDAQ:TXG) Q3: Strong Sales, Stock Jumps 13.1% [Yahoo! Finance]
10x Genomics, Inc. (TXG)
Last 10x genomics, inc. earnings: 2/18 04:01 pm
Check Earnings Report
Company Research
Source: Yahoo! Finance
On top of that, next quarter's revenue guidance ($156 million at the midpoint) was surprisingly good and 3.5% above what analysts were expecting. Its GAAP loss of $0.22 per share was 22.3% above analysts' consensus estimates. Is now the time to buy 10x Genomics? Find out in our full research report 10x Genomics (TXG) Q3 CY2025 Highlights: Revenue: $149 million vs analyst estimates of $142.4 million (1.7% year-on-year decline, 4.6% beat) EPS (GAAP): -$0.22 vs analyst estimates of -$0.28 (22.3% beat) Revenue Guidance for Q4 CY2025 is $156 million at the midpoint, above analyst estimates of $150.7 million Operating Margin: -21.6%, up from -27.4% in the same quarter last year Market Capitalization: $1.68 billion "Our team delivered a solid third quarter, and we continue to see notable enthusiasm for our single cell and spatial products," said Serge Saxonov, Co-founder and CEO of 10x Genomics. Company Overview Founded in 2012 by scientists seeking to overcome limitation
Show less
Read more
Impact Snapshot
Event Time:
TXG
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
TXG alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
TXG alerts
High impacting 10x Genomics, Inc. news events
Weekly update
A roundup of the hottest topics
TXG
News
- 10x Genomics (NASDAQ:TXG) was given a new $20.00 price target on by analysts at Morgan Stanley.MarketBeat
- 10x Genomics (NASDAQ:TXG) had its "sell (e+)" rating reaffirmed by analysts at <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a>.MarketBeat
- New ASTRA Consortium Unites Asia-Pacific Scientists to Build Pan-Cancer Spatial Atlas Powered by 10x Genomics' XeniumPR Newswire
- 10x Genomics Expands Flex Lineup with High-Throughput Single-Cell Assay Launch [Yahoo! Finance]Yahoo! Finance
- 1 Momentum Stock with Promising Prospects and 2 We Avoid [Yahoo! Finance]Yahoo! Finance
TXG
Earnings
- 11/6/25 - Beat
TXG
Sec Filings
- 11/25/25 - Form 4
- 11/25/25 - Form 4
- 11/25/25 - Form 4
- TXG's page on the SEC website